# Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

> **NCT00003425** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Kentucky** · enrollment: 25 (estimated)

## Conditions studied

- Breast Cancer
- Leukemia
- Lymphoma
- Neuroblastoma
- Ovarian Cancer
- Sarcoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** amifostine trihydrate
- **DRUG:** cyclophosphamide
- **DRUG:** melphalan
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00003425
- **Lead sponsor:** University of Kentucky
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-12
- **Primary completion:** 2002-07
- **Final completion:** —
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2013-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003425, "Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00003425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*